Podcast: Pioneering Fully Programmable Medicines

In the third of four features on Senda Biosciences, we spoke to Senda CEO Guillaume Pfefer and Senda Chief Platform Officer Stuart Milstein, about its platform technology, how it is building an atlas of natural nanoparticles, and how its work is leading to a pipeline of programmable medicines.

Companies to Watch – Senda Biosciences


This is part of the Big4Bio Company to Watch program for April 2023: Senda Biosciences
For more information on the series, click here.